By Bowman Cox 26 Jul 2021
Industry requests for deadline extensions, short-duration adjustments and other accommodations go nowhere as FDA expresses concerns about nitrosamines’ mutagenic potency.
While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.
SANDOZ GERMANY HAS LOST ITS LEADER Source: Shutterstock
Sandoz has conﬁrmed that Stephan Eder has resigned as the firm’s country head in Germany, and “will leave the company at the end of the month.” The company has not yet announced plans for a permanent replacement.
A spokesperson for Sandoz told Generics Bulletin that “after around three very successful years as country head for Sandoz Germany, Eder has taken a personal decision to take on a new challenge outside the Novartis Group.”
“As country head, he managed to strengthen our business in Germany and considerably expanded the growth momentum,” as well as “successfully developed the team,” the spokesperson commented.
With Sandoz Germany yet to appoint a new country head, Eder’s responsibilities are now being distributed between three members of the German Hexal subsidiary’s board on an interim basis: Matthias Weber, chief financial officer of Sandoz Germany; Wolfgang Späth, head of strategy, portfolio and market development; and Specialty head Peter Stenico.
Lupin Appoints Head Of Corporate Development
Lupin has announced the appointment of Alan Butcher as chief corporate development oﬃcer.
With over 30 years of experience in the pharmaceutical industry – including at Shire, Purdue and most recently as chief business officer of AMAG Pharmaceuticals – Butcher will lead Lupin’s global corporate development eﬀorts and will be responsible for the company’s global merger and acquisition, business development and licensing functions, “with a focus on continuing to build Lupin’s Specialty and Novel Products business.”
Based in Naples, Florida, Butcher will report to CEO Vinita Gupta.
“We are very pleased to welcome Alan to our leadership team,” Gupta said. “Alan’s experience in leading portfolio strategy and business development in speciality and big pharma companies will help us enhance our plans to evolve our Speciality and Novel Products business and optimize our capital allocation efforts to drive long-term growth and value.”
Hassard Leaves Coherus For Arrowhead
James Hassard, who served as senior vice-president of marketing and market access at Coherus BioSciences since 2016, has left the firm to join RNAi specialist Arrowhead Pharmaceuticals in the newly-created position of chief commercial officer.
Citing Hassard’s “25 years of commercial-related experience in the biopharmaceutical industry,” Arrowhead noted that he had “co-led the launch of Coherus’ first product,” the Udenyca (pegfilgrastim-cbqv) biosimilar, “which became one of the most successful pharmaceutical launches of 2019,” ending 2019 with a 20.5% share of the US pegfilgrastim market. (Also see "Coherus Is Confident After US Ranibizumab Filing" - Generics Bulletin, 22 Jan, 2020.) Hassard has also worked at Medivation and Amgen.
At Arrowhead, Hassard will be responsible for driving commercial strategy “and building the team and sales and marketing infrastructure necessary to support Arrowhead’s growing pipeline.”
Chris Anzalone, president and CEO of Arrowhead, described Hassard as “a seasoned and accomplished global biopharmaceutical professional who has been responsible for the launch of and commercial activities around multiple products.”
Catalent Makes Biologics Appointments
Contract development and manufacturing organization Catalent has appointed Karen Flynn as the president of biologics and chief commercial officer, replacing Barry Littlejohns who is retiring. She has joined the company’s executive leadership team and will report to Alessandro Maselli, Catalent’s president and chief operating officer.
“Karen arrives during a period of strong growth both in the biologics business and across the company as a whole, during which we are investing hundreds of millions of dollars in our biologics business and strengthening our commitment to ensuring that our customers have access to the best possible advanced biologic development technology and manufacturing solutions,” Maselli commented.
With over 30 years of experience in the pharmaceutical services industry, Flynn most recently held the position as senior vice-president and chief commercial officer for West Pharmaceutical Services. At Catalent, Flynn will assume global responsibility for the company’s biologics business, with current investments and including a $200m capital investment to expand drug substance manufacturing capacity in Madison, Wisconsin and drug product fill-finish capacity in Bloomington, Indiana.
Catalent has also named Mike Riley and Manja Boerman to become regional presidents for Biologics in North America and Europe respectively. Both Riley and Boerman have also joined Catalent’s executive leadership team and report directly to Flynn.
Medicines Patent Pool Seeks Associate Counsel
United Nations-backed public health organization the Medicines Patent Pool is soliciting applications for the role of associate counsel. The successful applicant “will work under the supervision of the general counsel as part of a small, dynamic legal team to provide sound legal stewardship and strategic advice in all facets of the organization’s affairs.”
“MPP is now expanding its activities to cover essential medicines, which requires engagement with many new stakeholders, including potential funders,” the organization noted.
Meanwhile, Belinda Wood has been appointed as senior director of government affairs for Gilead Sciences in Australia and New Zealand.
Wood – who was previously CEO of Australia’s Generic and Biosimilar Medicines Association – boasts 25 years of experience in the pharmaceutical and healthcare sector, including her recent role as deputy chief executive oﬃcer of the Pharmaceutical Society of Australia that saw her working in partnership with industry and government to shape national medicines policy and facilitate access to essential medicines.
And Simon-Kucher & Partners has announced the appointment of new partner Simone Seiter to join the company’s Frankfurt office and lead the Life Sciences division’s global consulting services around commercial strategy. Seiter previously worked at Capgemini and IQVIA and currently sits on the board of GenSights Biologics.
The strategy and marketing consultant says it is “strengthening its portfolio of services for companies in the pharmaceutical and biotech, medtech and consumer healthcare spaces by increasing its focus on commercial strategy.”
By Dean Rudge 26 Jul 2021
Having a year ago radically altered its business by offloading operations in India to rival Dr Reddy’s, India’s Wockhardt saw...
26 Jul 2021
The AAM’s latest study reveals that the Medicare Part D program continues to underperform compared to commercial plans in providing...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: